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Cardiac fibrosis is referred to as an excessive accumula-
tion of stromal cells and extracellular matrix proteins in 
the myocardium. Progressive fibrosis causes stiffening 
of the cardiac tissue and affects conduction of electri-
cal impulses, leading to heart failures in a broad range 
of cardiac conditions. At the cellular level, activation 
of the cardiac stromal cells and myofibroblast forma-
tion are considered as hallmarks of fibrogenesis. At the 
molecular level, transforming growth factor β (TGF-β) 
is traditionally considered as a master regulator of the 
profibrotic processes. More recently, the WNT signalling 
pathway has also been found to be implicated in the de-
velopment of myocardial fibrosis. In this review, we sum-
marize current knowledge on the involvement of TGF-β 
and WNT downstream molecular pathways to cardiac fi-
brogenesis and describe a crosstalk between these two 
profibrotic pathways. TGF-β and WNT ligands bind to 
different receptors and trigger various outputs. However, 
a growing body of evidence points to cross-regulation 
between these two pathways. It has been recognized 
that in cardiac pathologies TGF-β activates WNT/β-
catenin signalling, which in turn stabilizes the TGF-β/
Smad response. Furthermore both, the non-canonical 
TGF-β and non-canonical WNT signalling pathways, 
activate the same mitogen-activated protein kinases 
(MAPKs): the extracellular signal-regulated kinase (Erk), 
the c-Jun N-terminal kinases (JNKs) and p38. The cross-
talk between TGF-β and WNT pathways seems to play 
an essential role in switching on the genetic machinery 
initiating profibrotic changes in the heart. Better under-
standing of these mechanisms will open new opportuni-
ties for development of targeted therapeutic approaches 
against cardiac fibrosis in the future.
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INTRODUCTION
Cardiac fibrosis is characterized as an excessive ac-
cumulation of stromal cells and extracellular matrix pro-
teins (ECM) in the myocardium (Li et al., 2018). A broad 
range of pathologic cardiac conditions including myocar-
dial infarction, hypertension, myocarditis, hypertrophic 
or dilated cardiomyopathy is associated with cardiac tis-
sue remodelling and fibrosis development (Kong et al., 
2014). Fibrogenesis in the heart can be considered either 
as a repair or pathogenic process. In case of substan-
tial loss of native cardiac tissue, as for example following 
myocardial infarction, the damaged tissue is replaced by 
stromal cells preventing organ rupture. In cardiac condi-
tions without a loss of healthy tissue, fibrogenesis has no 
evident benefits and should be classified as a pathogenic 
process. Fibrosis causes not only stiffening of the cardi-
ac tissue leading to impaired mechanical contraction, but 
also can affect conduction of electrical impulses. Pro-
gressive fibrosis is, therefore, one of the major causes of 
heart failure.
Fibroblasts and myofibroblasts represent the most 
extensively characterised stromal cell types involved in 
fibrotic processes in the heart. In the traditional view, 
resident cardiac fibroblasts become activated, proliferate 
and became myofibroblasts, which produce an exces-
sive amount of ECM proteins, such as collagen type I 
and III. Myofibroblasts are characterised by expression 
of alpha-smooth muscle actin (α-SMA), which upregu-
lates their contractile activity and represents the most 
reliable marker of these cells (Gabbiani, 2003; Kurose & 
Mangmool, 2016; Travers et al., 2016). Growing body of 
evidence indicated that other cells present in the heart, 
including bone marrow-derived cells, epicardial epithelial 
cells and endothelial cells, can also contribute to myofi-
broblasts’ formation (Haudek et al., 2006; Kania et al., 
2009; Zeisberg et al., 2007; Zhou & Pu, 2011). Activation 
of fibroblasts and myofibroblast lineage differentiation 
is induced by various environmental stimuli and intra-
cellular molecules including profibrotic factors, such as 
transforming growth factor β (TGF-β), the WNT pro-
teins, members of renin-angiotensin-aldosterone system, 
yes-associated protein 1 (YAP)/transcriptional coactiva-
tor with PDZ-binding motif (TAZ) transcriptional regu-
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lators or various cytokines and chemokines (Kong et al., 
2014; Piersma et al., 2015). These multiple profibrotic 
inputs activate a complex signalling network that orches-
trates fibrotic response at the cellular and organ levels. 
To build a comprehensive model of cardiac fibrogenesis, 
a better understanding of crosstalks between individual 
pathways is needed. In this review, we specifically dis-
cuss the TGF-β and WNT downstream molecular path-
ways activated during cardiac fibrogenesis, with a special 
focus on the interplay between them.
TGF-β-DEPENDENT SIGNALLING PATHWAYS IN 
CARDIAC FIBROSIS
TGF-β is a ubiquitously expressed pleiotropic cy-
tokine controlling numerous cellular processes, including 
proliferation, differentiation, cytoskeletal reorganisation, 
and ECM protein synthesis. Beside its role in the de-
velopment, cancer and in maintenance of immunologi-
cal tolerance, TGF-β is considered as a master regulator 
of fibrogenesis (Meng et al., 2016; Yoshimura & Muto, 
2011). TGF-β protein occurs in three isoforms: TGF-β1, 
-β2 and -β3, which are encoded by distinct genes, but 
bind to the same receptors (Yoshimura & Muto, 2011). 
After translation, the TGF-β protein is produced in a 
latent form. Activation of TGF-β requires proteolytic 
cleavage and separation of two polypeptides from the 
active TGF-β form. Plasma membrane-bound integrins 
and extracellular proteases, such as plasmin and certain 
matrix metalloproteinases, are typically involved in cleav-
age of the latent TGF-β complex (Tran, 2012). Active 
TGF-β binds to the transmembrane TGF-β type II re-
ceptor, which in turn recruits and activates the TGF-β 
type I receptor. This stimulation initiates signal transduc-
tion through a canonical Smad-dependent and a number 
of Smad-independent signalling pathways. The ultimate 
consequence of the TGF-β signalling is transcriptional 
dysregulation of target genes which control cell prolif-
eration and production of structural and ECM proteins, 
such as collagens, laminins, fibronectin and many others 
(Branton & Kopp, 1999). TGF-β-dependent mechanisms 
contribute to fibrotic processes not only in the heart, 
but also in other organs, including kidney, liver, lung or 
skeletal muscle (Biernacka et al., 2011; Dooley & ten Di-
jke, 2012; Germano et al., 2009; Leask, 2007; Meng et al., 
2015; Paw et al., 2017; Tatler & Jenkins, 2012, Li et al., 
2004).
TGF-β represents a key profibrotic cytokine in car-
diac fibrogenesis and inhibition of its action successfully 
reduced or prevented fibrosis development in various 
animal models of cardiac disorders. In myocardial infarc-
tion model, TGF-β blockage with anti-TGF-β antibodies 
reduced collagen deposition and affected ECM protein 
production. Dysregulated tissue remodelling and insuf-
ficient scar formation in post-infarcted heart resulted in 
an increased mortality due to tissue rupture (Frantz et al., 
2008; Ikeuchi et al., 2004). In a rat model of pressure 
overload, neutralizing anti-TGF-β antibody successfully 
suppressed fibrosis and thereby prevented the develop-
ment of diastolic dysfunction (Kuwahara et al., 2002). 
Similar anti-fibrotic effects of anti-TGF-β antibody de-
livery were observed in a mouse model of experimen-
tal autoimmune myocarditis (Kania et al., 2009) and in a 
genetic model of spontaneous hypertrophic cardiomyo-
pathy (Teekakirikul et al., 2010). In a pressure overload 
model, the delivery of anti-TGF-β antibody inhibited 
profibrotic changes in cardiac interstitial cells, but not 
in cardiomyocytes. Interestingly, cardiomyocyte-specific 
deletion of TGF-β type II receptor suppressed not only 
cardiac hypertrophy, but also tissue remodelling induced 
by aortic banding, suggesting interplay between different 
cellular subsets and paracrine action of various profibrot-
ic factors during cardiac fibrogenesis (Koitabashi et al., 
2011).
Integrins and plasmin play important roles in proteo-
lytic activation of TGF-β. In cardiac fibroblasts, αvβ5 
and αvβ3 integrins promote latent TGF-β1 activation 
and control myofibroblast differentiation (Sarrazy et al., 
2014). It has been shown that activity of urokinase-type 
plasminogen activator (uPA) – an enzyme converting 
plasminogen to plasmin, also controls tissue remodel-
ling in the heart. Accordingly, mice overexpressing uPA 
developed spontaneous cardiac fibrosis (Moriwaki et al., 
2004), whereas mice lacking this enzyme showed im-
paired scar formation in the post-infarcted heart (Hey-
mans et al., 1999). Plasminogen activator inhibitor-1 
(PAI-1) is a potent inhibitor of uPA. It has been re-
ported that lack of PAI-1 enhanced myocardial fibrosis 
in aged mice. Importantly, PAI-deficient mice showed 
elevated TGF-β1 and 2 levels, as well as activation of 
the TGF-β downstream signalling pathway (Ghosh et al., 
2010). All of these data highlighted the pivotal role of 
TGF-β in cardiac fibrosis.
Smad-dependent signalling
The canonical response to TGF-β involves Smad pro-
teins and is referred to as Smad-dependent. Based on 
their function, Smad proteins can be classified into three 
categories: receptor activated Smads (R-Smad), com-
mon mediator Smads (Co-Smad) and inhibitory Smads 
(I-Smad). The TGF-β type I receptor specifically recog-
nizes R-Smads (Smad2 and Smad3) and phosphorylates 
them. Phosphorylated R-Smads bind to the Co-Smad 
protein (Smad4) forming a functional Smad2/3/4 com-
plex, which is translocated into nucleus and takes part in 
binding to the DNA sequences. Selectivity and affinity 
of the Smad2/3/4 complex for specific DNA structures 
is low and activation of a specific promoter strongly de-
pends on interaction of the Smad2/3/4 complex with 
other transcription factors. In contrast to R-Smads and 
Co-Smad, I-Smads (Smad6 and Smad7) are involved in 
repression of signal transduction. Smad6 competes with 
Smad4 for binding to R-Smad, whereas Smad7 binds to 
the TGF-β receptors (Hata et al., 1998; Hayashi et al., 
1997; Mehra & Wrana, 2002). Smad-dependent pathway 
is the main transducer of the TGF-β signalling and has 
been shown to play a key role in cardiac fibrogenesis in 
a number of in vivo and in vitro models. In a rat model 
of myocardial infarction, increased TGF-β levels in the 
scar tissue correlated with elevated abundance of Smad2, 
Smad3 and Smad4 proteins (Hao et al., 1999). Further-
more, Wang et al. demonstrated that an elevated level 
of TGF-β parallels with reduced amount of inhibitory 
Smad7 in the infarcted hearts for up to 8 weeks (Wang 
et al., 2002). The functional contribution of the Smad-
dependent pathway following myocardial infarction has 
been confirmed in Smad3-deficient mice, which showed 
reduced collagen III production and attenuated fibrosis 
in the infarcted hearts (Bujak et al., 2007). Smad3-defi-
cient mice also developed reduced fibrosis induced by 
angiotensin II infusion (Huang et al., 2010). In the pres-
sure overload model, TGF-β-Smad signalling in cardiac 
fibroblasts has been also implicated in the development 
of myocardial fibrosis. Fibroblast-specific deletion of 
Tgfbr1/2 or Smad3, but not Smad2, markedly reduced 
the pressure overload-induced fibrosis and inhibited 
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synthesis of the ECM proteins (Khalil et al., 2017). Fur-
thermore, ex vivo study on rat cardiac fibroblasts dem-
onstrated that TGF-β-induced collagen synthesis requires 
the Smad3/4 activity (Shyu et al., 2010). Mechanistically, 
pharmacological inhibition of Smad3/4 in the TGF-β-
activated fibroblasts suppressed transcription of endog-
lin – a membrane glycoprotein constituting a part of the 
TGF-β receptor complex. In addition, cardiac fibroblasts 
treated with Smad3 inhibitor also pointed to an impor-
tant role of the lysyl oxidase (LOX) – an enzyme that is 
necessary for cross-linking of collagen proteins (Volos-
henyuk et al., 2011). All of these data demonstrated the 
importance of the TGF-β-Smad axis in the development 
of cardiac fibrosis.
Smad-independent signalling
Stimulated TGF-β type I receptor activates not only 
the Smad-dependent response, but also triggers a num-
ber of Smad-independent signalling cascades, distinct 
from transcription. The signalling system involving 
phosphatidylinositol-3-kinase (PI3K) and protein ki-
nase B, also known as Akt, represents one example of 
the TGF-β-induced signal transduction pathway, which 
is independent of Smad proteins. In this pathway, acti-
vated PI3K phosphorylates and activates the Akt kinase, 
which in turn modulates several downstream effectors, 
such as glycogen synthase kinase-3β (GSK-3β), mam-
malian target of rapamycin (mTOR) and many others 
(Oudit et al., 2004; Zhang, 2009; Peterson & Schreiber, 
1998). The importance of PI3K/Akt signalling pathway 
has been implicated in specific aspects of cardiac fibrosis 
(Oudit et al., 2004). In particular, PI3K/Akt pathway was 
required for increased collagen synthesis in cardiac fibro-
blasts (Voloshenyuk et al., 2011). Furthermore, blockage 
of TGF-β dependent phosphorylation of Akt resulted in 
decreased expression of the LOX enzyme (Voloshenyuk 
et al., 2011). Inhibition of PI3K and Akt also indicated 
the importance of this pathway in TGF-β-dependent 
endoglin expression (Shyu et al., 2010). The PI3K/Akt 
pathway in cardiac fibrosis is, however, not regulated ex-
clusively by TGF-β. The direct impact of this pathway 
on cardiac fibrosis was also proved upon interleukin 
(IL)-18 and β-adrenergic stimulation (Oudit et al., 2003; 
Fix et al., 2011).
Another example of Smad-independent TGF-β signal 
transduction is a signalling pathway dependent on the 
RhoA-ROCK axis (Heasman & Ridley, 2008). RhoA 
belongs to the Rho GTP-ase family and functions as 
a “switch-protein”, transforming between active GTP-
bound (RhoA-GTP) and inactive GDP-bound (RhoA-
GDP) forms (Hubchak et al., 2009; Tsou et al., 2014; 
Zhan & Kanwar, 2014). The main effectors of RhoA 
pathway are Rho-associated, coiled-coil-containing pro-
tein kinases (ROCKs) existing in two isoforms, ROCK1 
and ROCK2. ROCKs regulate various important cellular 
functions, including proliferation, migration, differentia-
tion, cytoskeleton reorganisation and apoptosis (Shimizu 
& Liao, 2016). Experiments on various animal models 
indeed confirmed the importance of ROCKs in cardiac 
fibrogenesis. In ischemia-reperfusion model, ROCK1-
/- mice showed a markedly reduced collagen deposition. 
Furthermore, ROCK1 was shown to mediate transforma-
tion of bone marrow precursors into fibroblasts (Haudek 
et al., 2009). ROCK1–/– mice also developed less perivas-
cular and interstitial fibrosis in the pressure overload 
model induced by transverse aortic banding (Zhang et 
al., 2006). Experiments with haploinsufficient ROCK1+/– 
mice showed that partial reduction in ROCK1 levels 
was sufficient to prevent perivascular fibrosis induced 
by angiotensin II infusion, pressure overload or myocar-
dial infarction (Rikitake et al., 2005). The profibrotic role 
of ROCK1 was also confirmed in mice overexpressing 
Gαq, which develop cardiomyopathy at an old age. In 
this model, deletion of ROCK1 reduced myocardial fi-
brosis, while cardiac-specific overexpression of ROCK1 
caused acceleration of heart failure, cardiomyocyte ap-
optosis and fibrotic changes (Shi et al., 2010). In these 
fibrotic processes, ROCK1 is involved in myofibroblast 
differentiation and stress fibre formation (Hubchak 
et al., 2009; Shimizu & Liao, 2016). On the molecular 
level, ROCKs control polymerisation of monomeric G-
actin into F-actin – a major component of stress fibres. 
ROCKs were also shown to release myocardin-related 
transcription factors (MRTF), which together with serum 
response factor (SRF) induce expression of the profi-
brotic genes (Small et al., 2010; Tsou et al., 2014).
Stimulation with TGF-β can also result in direct ac-
tivation of non-canonical response dependent on mito-
gen-activated protein kinases (MAPKs), which transmit 
the signal from the cell membrane to the nucleus and 
regulate gene expression. Conventional MAPKs include 
the extracellular signal-regulated kinase 1 and 2 (Erk1/2 
or p44/42), the c-Jun N-terminal kinases (JNKs) and the 
p38 isoforms (α, β, γ, and δ). Signal transduction typically 
consists of a core module of three sequentially phospho-
rylated kinases: MAPK, MAPK kinase (MAPKK), and 
MAPKK kinase (MAPKKK) (Petrich & Wang, 2004). 
MAPKs play important role in the effector response, 
as they regulate the activity of transcriptional cofac-
tors cooperating with Smad proteins (Feng & Derynck, 
2005; Lee et al., 2007). The functional contribution of 
MAPKs to cardiac fibrosis has been documented in the 
literature. In a mouse model of myocardial infarction, 
enhanced phosphorylation of Erk1/2 and JNK were re-
ported to correlate with an increased degree of fibrosis 
(Sun et al., 2015), however other report confirmed an 
increased phosphorylation of p38 and Erk1/2, but not 
JNK (Yeh et al., 2010). In a rat model of pressure over-
load, all three major effector MAPKs: p38, Erk1/2 and 
JNK, became activated. Treatment with retinoic acid in-
hibited phosphorylation of these MAPKs and attenuated 
pathogenic cardiac remodelling (Choudhary et al., 2008). 
Recent data showed that inducible deletion of Mapk14 
(gene encoding p38α) in cardiac fibroblasts reduced the 
fibrotic response in post-infarcted heart (Molkentin et 
al., 2017). Study with TGF-β antagonist in spontaneous-
ly hypertensive rats confirmed involvement of p38 in 
cardiac fibrogenesis (Yan et al., 2009). In hypertensive 
heart, p38 is controlled by the injury responsive activat-
ing transcription factor 3 (ATF3) (Li et al., 2017). Fur-
thermore, TGF-β signalling through p38 controls the 
transient receptor potential canonical 6 (TRPC6), which 
promotes conversion of cardiac fibroblast to myofibro-
blast (Davis et al., 2012). Furthermore, all three MAPKs: 
p38, Erk1/2 and JNK have been also suggested to regu-
late TGF-β-dependent LOX expression in cardiac fibro-
blasts (Voloshenyuk et al., 2011). Activation of Erk1/2-
dependent pathway has been also functionally implicated 
in cardiac fibrosis. Mice with a laminin A/C gene muta-
tion develop myocardial fibrosis, which depends on acti-
vation of the TGF-β-Erk1/2 axis. Interestingly, Erk1/2 
activation was in part modulated by the TGF-β/Smad 
signalling (Chatzifrangkeskou et al., 2016). Moreover, 
TGF-β and Erk1/2 are also activated by high glucose in 
a mouse model of diabetic cardiomyopathy. Treatment 
with antioxidants suppressed activation of TGF-β and 
Erk1/2 and prevented development of myocardial fibro-
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sis in this model (Wu et al., 2016). Recently, IL-11 was 
identified as a new player in cardiac fibrosis. IL-11 was 
essential for activation of non-canonical Erk pathway in 
TGF-β-mediated fibrosis (Schafer et al., 2017). In the sig-
nal transduction cascade, MAPKKK plays a central role 
in regulation of the MAPK activity. TGF-β-activated ki-
nase 1 (TAK1) represents an important MAPKKK in 
TGF-β signalling (Biesemann et al., 2015). The relevance 
of TAK1-p38 axis activation in cardiac fibrogenesis was 
reported in myocardial infarction and pressure overload 
models (Matsumoto-Ida et al., 2006; Li et al., 2016). All 
of these data emphasize complexity of the Smad-inde-
pendent response in the TGF-β-mediated cardiac fibro-
genesis.
WNT SIGNALLING PATHWAYS IN CARDIAC FIBROSIS
WNT signalling represents another important signal 
transduction pathway which regulates organogenesis, 
cancer development and tissue fibrogenesis. The family 
of WNT ligands consists of highly evolutionarily con-
served glycoproteins encoded in humans by 19 genes 
(Garriock et al., 2007). Upon translation, the WNT pro-
teins undergo a series of post-translational modifications 
followed by a highly organized and tightly controlled 
exocytosis (Herr et al., 2012). Extracellular WNTs bind 
to transmembrane receptor complexes consisting of the 
Frizzled and the low-density lipoprotein receptor-related 
protein (LRP) families (Moon et al., 2004). After bind-
ing to receptor complexes, WNTs trigger various out-
puts in a β-catenin-dependent (canonical response) or 
independent (non-canonical response) manner. In the 
canonical response, binding of WNT1, WNT2b, WN-
T3a, WNT6 or WNT9b to the receptor complex acti-
vates the Dishevelled protein, which in turn inhibits 
GSK-3β-dependent degradation complex destroying the 
continuously synthetized β-catenin. This leads to stabi-
lisation and translocation of β-catenin into the nucleus, 
where β-catenin acts as a transcriptional coactivator 
which together with the T-cell factor (TCF) and the lym-
phoid enhancer factor (LEF) transcription factors initi-
ates transcription of the WNT target genes (Moon et al., 
2004; Tao et al., 2016). Frizzled receptor stimulation with 
WNT4, WNT5a or WNT11 can trigger gene transcrip-
tion independently of β-catenin by activating a planar 
cell polarity pathway and a calcium-dependent pathway. 
Signal transduction through the WNT/planar cell polar-
ity pathway involves activation of certain MAPKs (JNK 
and ERK1/2 kinases) and the RhoA-ROCK axis. In the 
WNT/calcium-dependent pathway, signal transduction is 
instead mediated through phospholipase C (PLC) activa-
tion, followed by Ca2+ release. The increase in free cyto-
plasmic Ca2+ levels subsequently activates protein kinase 
C (PKC), calmodulin kinase II and a Ca2+-sensitive en-
zyme, calcineurin. This might result in increased nuclear 
levels of transcription factor AP-1/c-Jun which regulates 
gene transcription (Bergmann 2010; Rao et al., 2010). 
Natural regulation of the WNT pathway predomi-
nantly occurs at the level of extracellularly secreted in-
hibitors. One of the most important natural inhibitors 
of the WNT signalling belongs to the family of secreted 
Frizzled-related proteins (sFRPs), which directly bind 
to the WNT proteins and prevent their interactions 
with the Frizzled receptors or directly bind to the Friz-
zled receptors themselves (Cruciat & Niehrs, 2013). The 
Dickkopf proteins represent another family of secreted 
proteins negatively regulating WNT signalling. Dickkopf 
proteins present in the extracellular space bind to LRP 
5/6 co-receptors triggering their internalization. Similarly, 
WNT-inhibitory factor 1 (WIF1) inhibits the WNT pro-
teins’ interaction with the receptor by binding to them 
(Surmann-Schmitt et al. 2009). Recently described WNT 
protein degrading enzymes, Tiki1 and Notum, represent 
another class of natural WNT inhibitors. Transmem-
brane metalloproteinase Tiki1 cleaves amino-terminal re-
gion of WNT ligands and thereby reduces their receptor-
binding ability (Zhang et al., 2016). Similarly, a secreted 
Notum enzyme specifically removes an acyl group from 
the WNT proteins which is needed for effective bind-
ing of WNTs to the Frizzled receptors (Kakugawa et al., 
2015). A natural regulation of WNT signalling is, how-
ever, not limited to inhibitors. Secreted R-spondin, for 
example, acts as a WNT ligand agonist enhancing ligand-
receptor clustering and inhibits Frizzled and LRP recep-
tor turn-over (Jin & Yoon, 2012).
Active WNT signalling has been implicated in car-
diac tissue remodelling. For example, enhanced WNT1 
expression was reported in the epicardium following 
acute ischaemic cardiac injury in mice (Duan et al., 2012), 
and increased levels of canonical (WNT2b, WNT9a) 
and non-canonical (WNT5a) WNTs were found in the 
myocardium of neonatal mice in response to cryoinjury 
(Mizutani et al., 2015). Increased activation of β-catenin 
and TCF/LEF have also been observed in human hearts 
with severe epicardial fibrosis (Ye et al., 2013). In recent 
years, a number of reports highlighted functional contri-
bution of WNT signalling to the cardiac fibrogenesis in 
various animal models. In rodent models of myocardial 
infarction, elimination of bioavailable WNTs with sFRP1, 
sFRP2 or sFRP4 was shown to reduce fibrosis and im-
prove cardiac function (Barandon et al., 2011; Fan et al., 
2018; He et al., 2010; Matsushima et al., 2010). Blockade 
of the Frizzled receptors with a specific pharmacological 
antagonist also improved post-infarction cardiac func-
tion and reduced collagen content (Laeremans et al., 
2011). Furthermore, in a mouse model of experimental 
autoimmune myocarditis, development of postinflamma-
tory fibrosis was successfully prevented by administrating 
sFRP2 (Blyszczuk et al., 2017). Cardiac tissue remodelling 
is also regulated by other secreted natural negative regu-
lators of WNT signalling. Dickkopf-3 has been shown 
to attenuate cardiac fibrosis in cardiac hypertrophy in-
duced by pressure overload or infusion with angiotensin 
II (Zhai et al., 2018; Zhang et al., 2014).
Regulation of WNT signalling in cardiac fibrosis is 
mediated not only through secreted factors, but also in-
tracellularly. Constitutive overexpression of the Dishev-
elled protein (which inhibits GSK-3β) activated canonical 
and non-canonical WNT signalling pathways and thereby 
induced spontaneous myocardial fibrosis and cardiac hy-
pertrophy (Malekar et al., 2010). Recent data specifically 
pointed to the important role of the canonical WNT 
signalling in cardiac fibroblasts. In myocardial fibrosis 
induced by transaortic constriction, genetic depletion of 
β-catenin in cardiac fibroblasts reduced interstitial fibro-
sis, although did not alter the number of activated cardi-
ac fibroblasts (Xiang et al., 2017). In the complementary 
approach, Lal and coworkers (Lal et al., 2014) demon-
strated that activation of the canonical WNT pathway by 
inhibiting GSK-3β in cardiac fibroblasts promoted fibro-
genesis in postinfarcted hearts.
In the context of myocardial fibrosis, at the cellular 
level, the WNT proteins have been mainly implicated in 
the activation of cardiac fibroblasts. WNT1 was shown 
to stimulate cardiac fibroblast proliferation and to up-
regulate profibrotic genes, including collagen I and en-
dothelin-1 (Duan et al., 2012). Such profibrotic response 
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in cardiac fibroblasts was also induced by WNT1-induced 
secreted protein-1 (WISP-1) (Colston et al., 2007). Com-
bined co-transfection of Frizzled receptors and stimula-
tion with WNT3a or WNT5a indicated the involvement 
of the canonical and non-canonical WNT pathways dur-
ing cardiac fibroblast differentiation (Laeremans et al., 
2010). Stimulation of cardiac fibroblasts with WNT5a 
showed Erk-dependent production of IL-6 and tissue in-
hibitor of metalloproteinase 1 (TIMP-1) (Abraityte et al., 
2017). Other data showed that stimulation by WNT1/
WNT5a or WNT3a ligands alone were insufficient to in-
duce effective pathological myofibroblast formation (Bly-
szczuk et al., 2017). Similarly, overexpression of β-catenin 
had no effect on myofibroblast lineage differentiation 
(Laeremans et al., 2010), but induced proliferation and 
suppressed apoptosis of the cardiac fibroblasts (Hahn et 
al., 2006).
Bioactivity, as well as transcriptional regulation of 
WNTs, are tightly controlled by sFRPs representing an 
important arm of the WNT system regulation (Cruciat 
& Niehrs, 2013; Sklepkiewicz et al., 2015). Accordingly, 
dysregulation of WNT-sFRP balance can affect fibrotic 
processes in the heart. Mice lacking sFRP1 showed in-
creased expression of WNT ligands, elevated levels of 
β-catenin, and enhanced αSMA expression and colla-
gen production in cardiac fibroblasts (Sklepkiewicz et 
al., 2015). Although elimination of bioavailable WNTs 
with exogenous sFRP2 reduced cardiac fibrosis in vivo 
(Blyszczuk et al., 2017; He et al., 2010), constitutive ex-
pression of sFRP2 in cardiac fibroblasts surprisingly ac-
tivated the WNT/β-catenin signalling and promoted fi-
broblast proliferation and expression of the ECM genes 
(Lin et al., 2016). Furthermore, sFRP2-deficient cardiac 
fibroblasts produced less collagen and sFRP2-deficient 
mice developed less fibrosis following myocardial in-
farction (Kobayashi et al., 2009). These data suggest that 
constitutive role of sFRP2 in cardiac fibroblasts is far 
more complex than suppression of profibrotic WNT sig-
nalling.
TGF-β-WNT CROSSTALK IN FIBROGENESIS
As demonstrated above, activation of the TGF-β and 
WNT signalling pathways plays important roles in fibrot-
ic processes in the heart. So far, our understanding of 
the direct interplay between these two pathways, specifi-
cally in the cardiac fibrogenesis, is limited.
Regulation of TGF-β by WNT
Little is known about regulation of the TGF-β produc-
tion by WNTs in the fibrotic process. Experiments on 
cardiac fibroblasts suggested that neither canonical nor 
non-canonical WNT signalling directly regulated TGF-β 
at the mRNA level (Laeremans et al., 2010). Canonical 
WNTs also failed to upregulate TGF-β in the lung fibro-
blasts (Lam et al., 2011). However, β-catenin-dependent 
WNT3a upregulated TGF-β production in mouse em-
bryonic fibroblasts (Carthy et al., 2011). Interestingly, in 
the cardiac fibroblasts, β-catenin signalling pathway was 
reported to control TGF-β production induced by fibro-
blast growth factor 23 (Hao et al., 2016). Furthermore, 
insight from non-cardiac models demonstrated transcrip-
tional regulation of PAI-1 by WNT1 in kidney epithelial 
cells, suggesting a potential negative regulation of TGF-β 
signalling by canonical WNT (He et al., 2010).
Regulation of canonical WNT by TGF-β
Regulation of the WNT/β-catenin pathway by TGF-β 
is much better documented. TGF-β has been implicat-
ed in production and secretion of the WNT proteins 
through a TAK1-dependent pathway in cardiac fibro-
blasts and in heart inflammatory cells (Blyszczuk et al., 
2017). Accordingly, in a mouse model of experimental 
autoimmune myocarditis and in a mouse model of pres-
sure overload, impaired profibrotic TGF-β responses 
were observed in the absence of β-catenin or upon phar-
macological inhibition of the β-catenin-dependent sig-
nalling, pointing to the involvement of canonical WNT 
pathway in this process (Blyszczuk et al., 2017; Xiang 
et al., 2017). Furthermore, TGF-β inducible PI3K/Akt 
pathway was also reported to inhibit GSK-3β (enzyme 
involved in β-catenin degradation) activity in the cardiac 
fibroblasts (Ma et al., 2017). Thus, TGF-β might directly 
activate the β-catenin-dependent pathway.
It has been shown that canonical WNT signalling can 
control profibrotic TGF-β response. Cardiac fibroblasts 
lacking GSK-3β showed enhanced profibrotic response 
and activation of Smad3 signalling, leading to enhanced 
cardiac tissue remodelling in a mouse model of myo-
cardial infarction (Lal et al., 2014). In addition, sirtuin 3 
has been proposed to suppress profibrotic TGF-β sig-
nalling through activation of GSK-3β in cardiac fibrosis 
(Sundaresan et al., 2016). These results suggested that 
β-catenin-dependent signalling also contributed to stabi-
lization of the canonical TGF-β response. Activation of 
the canonical WNT signalling in response to TGF-β and 
the functional contribution of this mechanism to fibrotic 
processes have been observed not only during cardiac 
fibrogenesis, but also in other organs, including skin 
(Akhmetshina et al., 2012), lungs (Xu et al., 2017) and the 
hair follicles (Lu et al., 2016; Si et al., 2017, Plikus et al., 
2012). Summarising, these data pointed to the important 
role of β-catenin-dependent pathway in TGF-β response. 
In the proposed mechanism, TGF-β activates WNT/β-
catenin signalling through production of WNT proteins 
and by direct deactivation of GSK-3β. Activated WNT/
β-catenin, in turn, stabilizes the TGF-β/Smad response. 
It seems that co-activation of these two pathways is re-
quired to trigger the effective fibrotic response.
Regulation of non-canonical WNT by TGF-β
In contrast to quite well-documented involvement of 
the canonical WNT signalling in the TGF-β response, 
much less is known about contribution of the non-
canonical WNT pathway. Although elevated levels of 
non-canonical WNT5a were detected in fibrotic hearts 
in mice and in humans (Abraityte et al., 2017; Blyszczuk 
et al., 2017), the interplay between TGF-β and WNT5a 
(or other non-canonical WNTs) remains mainly specula-
tive. Noteworthy, stimulation of the planar cell polarity 
pathway by non-canonical WNTs is known to activate 
MAPKs and Rho-dependent ROCKs, and thereby to 
regulate cytoskeletal organization and fibrotic response 
(Bergmann, 2010; Abraityte et al., 2017). As presented 
above, TGF-β also activates MAPK and ROCK path-
ways in a Smad-independent manner. It is possible that 
in the TGF-β stimulated cells, non-canonical WNTs sta-
bilize or modulate p38-, Erk-, JNK- and ROCK-depend-
ent responses in the fibrotic processes. However, the 
ultimate effect of such co-activation needs to be experi-
mentally addressed in the future.
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CONCLUSIVE REMARKS
Progressive fibrosis is a driving pathological force 
in many cardiac conditions. Understanding molecular 
mechanisms of this process could provide solutions to 
prevent progression or even to revert fibrotic changes in 
the heart. Mechanisms of cardiac fibrogenesis are rather 
complex and involve multiple players. In the light of the 
large number of identified profibrotic factors, under-
standing of interplays between these signalling pathways 
represents an emerging challenge in this field. As pre-
sented here, accumulating evidence points to the critical 
role of TGF-β and WNT pathways in the pathogenesis 
of fibrosis in the heart and in other organs. Although bi-
osynthesis of TGF-β and WNTs is quite well described, 
the bioavailability of these profibrotic factors in various 
cardiac pathologies remains largely elusive. Unlike typical 
cytokines and chemokines, biological activity of TGF-β 
and WNTs is strongly regulated in the extracellular 
space. Future research should focus more on identifying 
mechanisms regulating bioavailability of these profibrotic 
agents.
As discussed in this review, the crosstalk between 
TGF-β and WNT pathways seems to be essential in 
switching on the genetic machinery of the profibrotic 
changes. The crosstalk between these two pathways in-
cludes not only positive feedback loops, but also com-
mon downstream signalling molecules and outputs 
(Fig. 1). Experimental data demonstrated that only 
highly organised and coordinated response of these mul-
tifaceted mechanisms effectively translates into fibrotic 
changes at the cellular and tissue levels. It is important 
to note that both, the TGF-β and WNT pathways, regu-
late a number of various cellular processes and play fun-
damental roles in organogenesis and in carcinogenesis. 
Thus, consequences of uncontrolled systemic dysregula-
tion of these signalling pathways might be fatal. It seems 
that precise targeting of specific aspects of the TGF-β-
WNT signalling network, rather than its global inhibi-
tion, is a better strategy for the development of success-
ful side effect-free antifibrotic approaches. Identification 
of these new targets requires, however, a better under-
standing of molecular mechanisms.
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